Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate ...

Wolfe Research downgraded shares of the maker of sleep-apnea airway machines to Underperform from Peer Perform.

ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...

Wolfe Research has recently reduced Resmed Inc (RMD) stock to Underperform rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 4, 2024, Needham had reduced the stock ...

ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...

Healthcare technology company ResMed 's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...

Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s ...

ResMed Inc. closed $4.30 below its 52-week high ($255.18), which the company reached on September 9th.